News for Sanofi Stock (SNY)

Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III

Zacks Investment Research • Monday

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

GlobeNewsWire • Monday

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

GlobeNewsWire • 12/19/24

SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study

Zacks Investment Research • 12/18/24

Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?

Zacks Investment Research • 12/18/24

Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's

Investopedia • 12/17/24

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

WSJ • 12/17/24

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

Benzinga • 12/17/24

BrightInsight Expands Global Digital Partnership with Sanofi to Build Drug Companion Apps for its Major Specialty Therapies

GlobeNewsWire • 12/17/24

Teva, Sanofi say drug to treat IBD met primary targets

Reuters • 12/17/24

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease

GlobeNewsWire • 12/17/24

SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS

Zacks Investment Research • 12/13/24

Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis

GlobeNewsWire • 12/13/24

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer

Reuters • 12/12/24

FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates

Zacks Investment Research • 12/11/24

Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US

GlobeNewsWire • 12/11/24

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients

GlobeNewsWire • 12/09/24

Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP

GlobeNewsWire • 12/07/24

Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program

Business Wire • 12/06/24

Press Release: Availability of the revised financial statements for Sanofi excluding Opella

GlobeNewsWire • 12/06/24

Global Fortune 500 Company Doubles Down on Beijing E-Town with Back-to-Back Investments Over Three Years: Insights from the Sanofi Project into E-Town's Business Environment

GlobeNewsWire • 12/05/24

China's First International Pharma Biotherapeutic API Project Launched in Beijing E-Town -- Sanofi Invests Approximately 1 Billion Euros in New Insulin Production Facility

GlobeNewsWire • 12/04/24

Sanofi to Invest $1 Billion in New Insulin Manufacturing Base in China

WSJ • 12/03/24

Sanofi to invest $1 bln in insulin production site in Beijing, local authority says

Reuters • 12/02/24

Pharma giant Sanofi opens $595 million vaccine facility in Singapore to boost preparedness for potential pandemics

CNBC • 11/27/24